Literature DB >> 29696341

Risk stratification in hypertrophic cardiomyopathy.

S Marrakchi1,2, I Kammoun3,4, E Bennour3,4, L Laroussi3,4, S Kachboura3,4.   

Abstract

Sudden cardiac death (SCD) is the most devastating complication of hypertrophic cardiomyopathy (HCM). The greatest challenge in the management of HCM is identifying those at increased risk, since an implantable cardioverter-defibrillator (ICD) is a potentially life-saving therapy. We sought to summarize the available data on SCD in HCM and provide a clinical perspective on the current differing and somewhat conflicting data on risk stratification, with balanced guidance regarding rational clinical decision-making. Additionally, we sought to determine the status of the current implementation of guidelines compiled by HCM experts worldwide. The HCM Risk-SCD model helps improve the risk stratification of HCM patients for primary prevention of SCD by calculating an individual risk estimate that contributes to the clinical decision-making process. Improved risk stratification is important for decision-making before ICD implantation for the primary prevention of SCD.

Entities:  

Keywords:  Hypertrophy; Implantable cardioverter-defibrillator; Myocardium; Risk assessment; Sudden cardiac death

Mesh:

Year:  2018        PMID: 29696341     DOI: 10.1007/s00059-018-4700-8

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  152 in total

1.  Enlarged left atrium and sudden death risk in hypertrophic cardiomyopathy patients with or without atrial fibrillation.

Authors:  Yuichiro Minami; Shintaro Haruki; Bun Yashiro; Tsuyoshi Suzuki; Kyomi Ashihara; Nobuhisa Hagiwara
Journal:  J Cardiol       Date:  2016-02-20       Impact factor: 3.159

2.  Cardiac magnetic resonance imaging findings predict major adverse events in apical hypertrophic cardiomyopathy.

Authors:  Kate Hanneman; Andrew M Crean; Lynne Williams; Hadas Moshonov; Susan James; Laura Jiménez-Juan; Christiane Gruner; Patrick Sparrow; Harry Rakowski; Elsie T Nguyen
Journal:  J Thorac Imaging       Date:  2014-11       Impact factor: 3.000

Review 3.  Prognostic Value of LGE-CMR in HCM: A Meta-Analysis.

Authors:  Zhen Weng; Jialu Yao; Raymond H Chan; Jun He; Xiangjun Yang; Yafeng Zhou; Yang He
Journal:  JACC Cardiovasc Imaging       Date:  2016-07-20

4.  Late gadolinium enhancement on cardiac magnetic resonance represents the depolarizing and repolarizing electrically damaged foci causing malignant ventricular arrhythmia in hypertrophic cardiomyopathy.

Authors:  Naka Sakamoto; Yuichiro Kawamura; Nobuyuki Sato; Asami Nimura; Motoki Matsuki; Atsushi Yamauchi; Takayasu Kanno; Yasuko Tanabe; Toshiharu Takeuchi; Shunsuke Natori; Yasuaki Saijo; Tamio Aburano; Naoyuki Hasebe
Journal:  Heart Rhythm       Date:  2015-02-12       Impact factor: 6.343

5.  Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy.

Authors:  Rory O'Hanlon; Agata Grasso; Michael Roughton; James C Moon; Susan Clark; Ricardo Wage; Jessica Webb; Meghana Kulkarni; Dana Dawson; Leena Sulaibeekh; Badri Chandrasekaran; Chiara Bucciarelli-Ducci; Ferdinando Pasquale; Martin R Cowie; William J McKenna; Mary N Sheppard; Perry M Elliott; Dudley J Pennell; Sanjay K Prasad
Journal:  J Am Coll Cardiol       Date:  2010-06-25       Impact factor: 24.094

6.  Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.

Authors:  Dulce Brito; J Sampaio Matias; Luís Sargento; Maria João Cabral; Hugo C Madeira
Journal:  Rev Port Cardiol       Date:  2004-12       Impact factor: 1.374

7.  Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy.

Authors:  Barry J Maron; Susan A Casey; Raymond H Chan; Ross F Garberich; Ethan J Rowin; Martin S Maron
Journal:  Am J Cardiol       Date:  2015-06-04       Impact factor: 2.778

Review 8.  Hypertrophic obstructive cardiomyopathy.

Authors:  Josef Veselka; Nandan S Anavekar; Philippe Charron
Journal:  Lancet       Date:  2016-11-30       Impact factor: 79.321

9.  Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance.

Authors:  A Selcuk Adabag; Barry J Maron; Evan Appelbaum; Caitlin J Harrigan; Jacqueline L Buros; C Michael Gibson; John R Lesser; Constance A Hanna; James E Udelson; Warren J Manning; Martin S Maron
Journal:  J Am Coll Cardiol       Date:  2008-04-08       Impact factor: 24.094

10.  Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients.

Authors:  Lorenzo Monserrat; Perry M Elliott; Juan R Gimeno; Sanjay Sharma; Manuel Penas-Lado; William J McKenna
Journal:  J Am Coll Cardiol       Date:  2003-09-03       Impact factor: 24.094

View more
  2 in total

1.  Can positron emission tomography help stratify the risk of sudden cardiac death in patients with hypertrophic cardiomyopathy?

Authors:  G Neal Kay
Journal:  J Nucl Cardiol       Date:  2018-05-14       Impact factor: 5.952

2.  Real-world clinical validity of cardiac magnetic resonance tissue tracking in primitive hypertrophic cardiomyopathy.

Authors:  Pierpaolo Palumbo; Francesco Masedu; Camilla De Cataldo; Ester Cannizzaro; Federico Bruno; Silvia Pradella; Francesco Arrigoni; Marco Valenti; Alessandra Splendiani; Antonio Barile; Andrea Giovagnoni; Carlo Masciocchi; Ernesto Di Cesare
Journal:  Radiol Med       Date:  2021-12-11       Impact factor: 3.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.